Featured Courses

Pediatric Psoriasis: Informed Decisions That Improve Clinical Outcomes | myCME

AMA PRA Category 1 Credit(s)^TM

Hear expert insights on effective treatments for psoriasis and how to involve families and young patients in care.

Signals of Change in the Management of Atopic Dermatitis | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, CNE Contact Hour(s)

This CMEO webcast blends faculty presentation and discussion to assist learners in applying clinical tools to establish disease severity, translating how new agents will impact clinical practice, and integrating patient preferences and treatment goals into shared decision-making (SDM).

The Role of TYK2 Inhibitors in the Treatment of Psoriasis

AMA PRA Category 1 Credit(s)^TM

How are TYK2 inhibitors different from other JAK inhibitors? This review provides knowledge you need on investigational TYK2 inhibitors and personalized psoriasis treatment plans.

What Does the Future Hold in the Treatment of Atopic Dermatitis?

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

Part of the National Eczema Association’s Coalition United for Better Eczema Care (CUBE-C) educational series, this activity will the impact AD has on a patient’s QOL, as well as current and emerging agents for the treatment of AD.

Advanced Cutaneous Squamous Cell Carcinoma in the Era of Systemic Immunotherapy

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

This webcast series increases awareness about risk cSCC stratification and prognosis, as well as the efficacy, safety, and role of targeted therapies for advanced cSCC.

Hitting the Target with IL-23 Inhibitors in Psoriatic Arthritis | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, CNE Contact Hour(s)

In this CME Outfitters Live and OnDemand activity, expert faculty will focus on assessment, treatment, and management strategies to provide patients with the best treatment aligned with evolving evidence and expert recommendations.

Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), AAPA Category I CME credit

The increasing incidence of Atopic dermatitis (AD) and poor recognition of the disease in some patient groups is a public health concern. Education about current and emerging long-term strategies to AD management is crucial for clinician interpretation and application to clinical practice.

Adult patients with Moderate-to-Severe Atopic Dermatitis

AMA PRA Category 1 Credit(s)^TM

This case-based activity features two expert physicians as well as a longtime patient with AD to provide 360-degree insight on the core issues involved in the management of the condition in adults.

Management and Treatment of Atopic Dermatitis in Patients of Color

AMA PRA Category 1 Credit(s)^TM

This case-based activity features insight from two expert physicians as well as an AD patient on some of the issues faced by commonly patients with skin of color and offers suggestions on how to overcome specific barriers to care.

Emerging and Investigational Therapies for Moderate-to-Severe AD

AMA PRA Category 1 Credit(s)^TM

This case-based activity features insight from two expert physicians as well as a caregiver of a longtime AD patient to provide 360-degree insight on current and potential future strategies for the management of moderate-to-severe AD.

The Management of Common AD-Related Comorbidities

AMA PRA Category 1 Credit(s)^TM

In this case-based activity, two physician experts in the management of AD are joined by a longtime patient with AD to discuss some of the most significant challenges patients with AD and comorbidities face on a day-to-day basis.

JAK/TYK2 Inhibition: New Frontiers in the Treatment of Psoriasis | myCME

AMA PRA Category 1 Credit(s)^TM

This activity will provide clinicians with a solid foundation for understanding the pathophysiology of psoriasis along with other autoimmune diseases, how this pathophysiology informs treatment options, and the most recent clinical trial data for current and emerging agents and management recommendations available to guide therapy selection.